Across TCGA pan-cancer cohorts, LRRCC1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LRRCC1 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LRRCC1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated LRRCC1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.
UCEC, SCLC, and PRAD are the cancer types where LRRCC1 Mutation most reproducibly stratifies survival.